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ABSTRACT
The b common-signaling cytokines interleukin (IL)-3, granulocyte-macrophage colony stimulating factor
(GM-CSF) and IL-5 stimulate pro-inﬂammatory activities of haematopoietic cells via a receptor complex
incorporating cytokine-speciﬁc a and shared b common (bc, CD131) receptor. Evidence from animal
models and recent clinical trials demonstrate that these cytokines are critical mediators of the
pathogenesis of inﬂammatory airway disease such as asthma. However, no therapeutic agents, other than
steroids, that speciﬁcally and effectively target inﬂammation mediated by all 3 of these cytokines exist. We
employed phage display technology to identify and optimize a novel, human monoclonal antibody
(CSL311) that binds to a unique epitope that is speciﬁc to the cytokine-binding site of the human bc
receptor. The binding epitope of CSL311 on the bc receptor was deﬁned by X-ray crystallography and site-
directed mutagenesis. CSL311 has picomolar binding afﬁnity for the human bc receptor, and at
therapeutic concentrations is a highly potent antagonist of the combined activities of IL-3, GM-CSF and IL-
5 on primary eosinophil survival in vitro. Importantly, CSL311 inhibited the survival of inﬂammatory cells
present in induced sputum from human allergic asthmatic subjects undergoing allergen
bronchoprovocation. Due to its high potency and ability to simultaneously suppress the activity of all 3 b
common cytokines, CSL311 may provide a new strategy for the treatment of chronic inﬂammatory
diseases where the human bc receptor is central to pathogenesis. The coordinates for the bc/CSL311 Fab
complex structure have been deposited with the RCSB Protein Data Bank (PDB 5DWU).
Abbreviations:mAb, monoclonal antibody; IL-3, interleukin-3; IL-5, interleukin-5; GM-CSF, granulocyte-macrophage
colony stimulating factor; STAT-5, Signal Transducer and Activator of Transcription-5; SPR, Surface Plasmon Reso-
nance; D, domain; CDR, Complementarity-Determining Region; CFU, Colony Forming Unit; WT, wild type; Eo/B,
Eosinophil/Basophil; IC50, half maximal inhibitory concentration; KD, dissociation constant; ECmax, maximal effective









The pleiotropic cytokines interleukin (IL)-3, IL-5 and granulo-
cyte-macrophage colony stimulating factor (GM-CSF) play crit-
ical and overlapping roles in the differentiation and function of
certain myeloid cells. While IL-3 and IL-5 production is largely
T-cell restricted, GM-CSF is produced by many cells, including
T and B cells, endothelial cells, ﬁbroblasts, mast cells, macro-
phages, and eosinophils.1 They are important mediators of
host defense and innate immunity, but can also contribute
signiﬁcantly to the development and progression of inﬂamma-
tory pathologies, including chronic inﬂammatory airway dis-
eases such as asthma. Asthma is a common but complex and
heterogeneous chronic disorder in humans that is characterized
by airway inﬂammation, reversible airway obstruction, mucus
hypersecretion, airway wall remodeling and airway hyperres-
ponsiveness (AHR).2 There is considerable evidence that multi-
ple haematopoietic cell types, including eosinophils, neutrophils
and basophils, contribute to the chronic inﬂammation seen in
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severe asthma phenotypes. The airway inﬂammation in different
asthma phenotypes can be characterized, based on induced
sputum analysis, as being either eosinophilic, i.e., sputum eosi-
nophils greater than 3.0%, neutrophilic i.e., sputum neutrophils
greater than 76%, mixed granulocytic (increased sputum eosino-
phils and neutrophils) or paucigranulocytic (normal levels of
eosinophils and neutrophils).3 However, individual patients
with severe asthma can have overlapping and heterogeneous
inﬂammatory proﬁles with diverse symptoms and variable
responses to therapy.4 The exact mechanisms of pathogenesis
are incompletely understood, and no cure currently exists. Cur-
rent management relies on the use of steroids and long-acting b
adrenergic receptor agonists; however, many patients exhibit
steroid-resistant responses, and in others steroid effectiveness
needs to be carefully balanced with their signiﬁcant side-effects.
Elevated levels of cytokines, particularly the b common (bc, bcR,
CD131, CSF2RB), receptor family of cytokines, potently stimu-
late haematopoietic cell function, and, together with thymic
stromal lymphopoietin (TSLP), interleukins-4, -13, -17 -25 and
-33, these molecules co-ordinate an inﬂammatory inﬁltration of
lymphoid and myeloid cells, extensive mucosal remodeling and
mucus hypersecretion in the affected tissue.5
GM-CSF, which is abundantly produced by lung epithe-
lial cells, promotes the differentiation and proliferation of
granulocyte/macrophage progenitor haematopoietic cells
and regulates the survival and function of neutrophils, eosi-
nophils, macrophages and dendritic cells.5 In asthma and
chronic obstructive pulmonary disease (COPD), GM-CSF
expression is elevated in sputum and bronchoalveolar lavage
ﬂuid (BALF).6 IL-3 acts at the early stages of hematopoiesis
and synergizes with other growth factors for haematopoietic
development.1 It also modulates the activity of mature cell
types such as monocytes, dendritic cells, megakaryocytes,
mast cells and can activate eosinophils and prime basophils
to release histamine. Increased levels of IL-3 in BALF are
typically present after allergen challenge.7 IL-5 is more cell
type-speciﬁc, regulating the production and release of
mature eosinophils from the bone marrow into the circula-
tion. Elevated levels of IL-5 have been found in the serum
and airway ﬂuid of patients with asthma.8 In asthmatic sub-
jects, IL-5 inhalation increased AHR as well as the recruit-
ment of activated eosinophils to the airways.9 An early
stage in IL-5-driven development of eosinophils is upregula-
tion of the IL-5 receptor a chain (IL-5Ra) expression on
the surface of CD34C progenitor cells.10 An increase in the
percentage of bone marrow CD34C/IL-5RaC cells 24 hours
after inhaled allergen challenge has been noted in dual
responder allergic subjects.11
IL-3, IL-5, and GM-CSF bind with low afﬁnity to their spe-
ciﬁc a chain receptor and the responsiveness of myeloid cells to
a particular cytokine depends on which a chain is expressed.
Upon cytokine binding to an a chain receptor, a shared com-
mon b receptor, which on its own is unable to bind ligand or
initiate signaling, is recruited to the low-afﬁnity complex and
converts cytokine binding to a high-afﬁnity interaction.12 Stud-
ies of mouse models of allergic inﬂammation, using mice deﬁ-
cient in bc and an IL-3-speciﬁc b homodimer (bIL-3) unique to
mice (bc
¡/¡and bIL-3¡/¡ designated bc¡/¡mice), demonstrated
that signaling through bc by IL-3, IL-5 and GM-CSF was critical
for the development and function of immune cells associated
with the inﬂammatory response and detrimental pathology.13 In
bc
¡/¡ mice, allergen-induced expansion and accumulation of
eosinophils in the peripheral blood, peribronchial tissue and air-
way lumen is abolished.13 In addition, bc deﬁciency resulted in a
signiﬁcant reduction in airway hypersensitivity, mucus hyperse-
cretion and production of antigen-speciﬁc IgE. In contrast, stud-
ies targeting individual ligands such as IL-5 and GM-CSF
resulted in only partial ablation of myeloid cell function and
diminution of the hallmark features of asthma.14
As a consequence of the evidence supporting a key role for
haematopoietic cells, particularly those of the myeloid lineage,
and the bc-signaling cytokines in the development and progres-
sion of inﬂammatory airways disease, a number of therapeutic
monoclonal antibodies (mAbs) targeting individual bc-signal-
ing cytokines or their receptor a chains are or have been in
clinical development for asthma.15-17 While these agents,
including those targeting human GM-CSF,18 human IL-5
(mepolizumab, reslizumab)19 and human IL-5Ra (benralizu-
mab),20 are useful in selected subsets of asthma patients, it is
likely that their broader application will be limited by the cellu-
lar redundancy of the bc cytokines and the variable nature of
the inﬂammatory cell inﬁltrate that can underpin the asthma
phenotype. These major limitations have been recently
highlighted by the failure of KB003, an anti-GM-CSF mAb to
meet its primary clinical endpoints in a Phase 2 asthma study21
(ClinicalTrials.gov Identiﬁer: NCT01603277). Recent studies
have conﬁrmed that treatment with mepolizumab, reduced reli-
ance on glucocorticoids, reduced exacerbations and improved
several measures of asthma control in a subpopulation of
patients stratiﬁed for severe eosinophilic asthma.15,22,23 How-
ever, since eosinophils only partially contribute to asthma,
modest improvements in AHR have been observed.24 Ideally, a
therapeutic agent able to effectively target the common cyto-
kine binding site in bc could inhibit the activity of all 3 bc-sig-
naling cytokines and affect the functional activity of the
haematopoietic cells that they regulate. A bc-speciﬁc mAb,
BION-1, that simultaneously inhibits IL-3, GM-CSF and IL-5
activities has been described previously, but its low potency
would limit any therapeutic applications.25
In this study, we used phage display to identify a rare
positive mAb, which after multiple rounds of combinatorial
afﬁnity maturation, resulted in a bc-speciﬁc, fully human
mAb designated CSL311. Through directly blocking the
ability of each cytokine to interact with bc, CSL311 is a
potent inhibitor of IL-3-, GM-CSF- and IL-5-mediated
functions at therapeutic doses. We further showed that
CSL311 is a potent inhibitor of the combined effects of IL-
3, GM-CSF and IL-5 on the survival of eosinophils, key
effector cells involved in the pathogenesis of asthma. Nota-
bly, we demonstrated, using cells cultured ex vivo from
mild atopic asthmatic subjects undergoing inhaled allergen
challenge, that CSL311 can block eosinophil, basophil and
neutrophil survival and signiﬁcantly reduce the numbers of
eosinophil (Eo)/basophil (B)-colony forming units (CFU)
and granulocyte macrophage (GM)-CFU derived from
peripheral blood and bone marrow CD34C progenitors. The
unique mode of action of CSL311 and ability to target 3
cytokines simultaneously offers distinct advantages for the
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treatment of inﬂammatory disorders that involve the bc-sig-
naling cytokines, including severe asthma, nasal polyposis,
and hyper-eosinophilic syndromes.26
Results
Generation of a neutralizing, fully human mAb with
speciﬁcity for the human bc homodimer
The human bc receptor exists as a preformed intertwined
homodimer with a unique arrangement for the cytokine
binding site (Site 2) that comprises residues from domain 1
(D1) of one bc monomer and domain 4 (D4) of the second
bc monomer.
27 Previous studies of BION-1, a hybridoma-
derived anti-bc mAb isolated from mice immunized
with the extracellular D4 of bc, and thus only part of the
Site 2 cytokine binding region, is of relatively high afﬁnity
(KD D 5 nM) but low potency.25 Its weak antagonist activity
was conﬁrmed in IL-3-, GM-CSF- and IL-5-induced TF-1
erythroleukemic cell28 proliferation assays (Fig. 1A). We
therefore screened a semi-synthetic human Fab phage
library with a diversity of 1010, using the entire recombinant
extracellular region of the bc homodimer, to facilitate the
identiﬁcation of Fabs targeting an epitope spanning regions
of both D1 and D4, thus enabling the simultaneous antago-
nism of IL-3, GM-CSF and IL-5 with high potency. Of the
3548 individual phage clones selected, 209 unique clones
were speciﬁc to bc. Competitive phage ELISA was used to
screen for the highest afﬁnity clones.
From these studies, 29 unique clones were chosen and refor-
matted as whole human IgG4-kappa antibodies (IgG4pK) con-
taining a hinge mutation to increase stability,29 and screened
for their ability to inhibit GM-CSF-induced TF-1 cell prolifera-
tion. Remarkably, only a single antibody, 9A2, was identiﬁed
that could dose-dependently inhibit the downstream prolifer-
ative response of TF-1 cells to GM-CSF. 9A2 was also able
inhibit TF-1 proliferative responses to IL-3, and IL-5 (Fig. 1A),
and IL-3- and GM-CSF-induced STAT-5 phosphorylation
(Fig. 1B and Fig. 1C, Table S1). As expected, 9A2 bound speciﬁ-
cally to cells expressing bc, but not to cells expressing either
human IL-3Ra, human GM-CSFRa (GMRa ) or human IL-
5Ra alone (Fig. 1D). TF-1 cells also proliferate in response to
IL-6, IL-4, Epo and SCF.30 9A2 did not block TF-1 proliferation
in response to any of these factors (data not shown), conﬁrm-
ing that 9A2 inhibited the biological activity of only the bc-sig-
naling cytokines.
Although 9A2 completely inhibited IL-3 activity, it was a
very weak antagonist of GM-CSF and IL-5 activity (Fig. 1A)
with an IC50 of ~456 nM in the GM-CSF-mediated TF-1 cell
proliferation assay (Table S1). Surface plasmon resonance
(SPR) analysis of a 9A2 Fab fragment binding to immobilized
extracellular domain of the bc homodimer determined an equi-
librium dissociation constant (KD) of 49 nM (Table S1). We
hypothesized that the low potency of 9A2 was a consequence of
its low afﬁnity due to a relatively fast off-rate (Table S1 and
Fig. 2A). Afﬁnity maturation of this unique antibody was there-
fore undertaken in order to identify variants with a higher
afﬁnity for bc and the capacity to completely inhibit IL-3-,
Figure 1. 9A2 inhibits IL-3/GM-CSF/IL-5 induced TF-1 proliferation and STAT5 phosphorylation, and binds speciﬁcally to the human bc receptor. (A) TF-1 cells were starved
of growth factor for 18 h and then treated with test antibodies BION-1 () and 9A2 () for 30 min prior to the addition of cytokines (IL-3, GM-CSF, IL-5) for 72 hr. Prolifera-
tion was assayed by [H3]-thymidine incorporation and the IC50 values plotted. TF-1-bla cells were starved of growth factor for 18 hours and then treated with 9A2 for 30
minutes prior to the addition of cytokines. For pStat5 assays TF-1-bla cells were incubated with (B) IL-3 (10 ng/ml) or (C) GM-CSF 3 ng/ml) at 37C for 5 h and FRET B/G
substrate was added for 2.5 hours prior to reading the output on an Envision plate reader. Histograms show mean and standard error of technical replicates. Representa-
tive experiments are shown. (D) FreeStyleTM 293-F cells were transiently transfected with cDNAs encoding the bcR, the GMRa, the IL-3Ra and the IL5Ra and analyzed by
ﬂow cytometry. Control antibodies to the human bcR, GMRa, the IL-3Ra or the IL-5Ra conﬁrmed expression of these proteins in the transfected cells.
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GM-CSF- and IL-5-mediated receptor activation at clinically
relevant concentrations.
Seven phage libraries each covering 6 amino acid residues
and randomized for all 19 possible amino acids (excluding cys-
teine) were generated to systematically analyze the contribution
of each 9A2 complementarity-determining region (CDR) to the
binding of the antibody to bc. CDR2 of the light chain was
omitted from the analysis as its interaction with antigens is rel-
atively infrequent.31 Following 5 rounds of selection, 24 ran-
domly selected clones from each library were sequenced.
Clones from the L3.2 library failed to form a consensus
sequence and were excluded from further study. Unique var-
iants from all other libraries were converted to human IgG4pK
molecules, expressed, puriﬁed and screened in TF-1 prolifera-
tion assays. Variants from all libraries were either similar to or
showed an improvement in potency against GM-CSF com-
pared to parental 9A2 (Table S1 and Fig. 3A), with the excep-
tion of those targeting CDR3 from the light chain of parental
9A2. Improved dissociation rates were observed for all variants
that showed increased afﬁnities (Table S1 and Fig. 2B). Potency
improvements against GM-CSF were greatest for clones
derived from heavy chain CDR1 (H1.1) and CDR2 (H2.1)
libraries (Fig. 3A). Variant 9A2-VR24 originated from the
heavy chain CDR1 library (H1.1) and compared with parental
9A2 had afﬁnity (KD D 0.46 nM, Fig. 2B) and GM-CSF potency
improvements of 106-fold and 182-fold, respectively (Table S1,
and Fig. 3A). The most potent CDR2 (H2.1) variant (9A2-
VR39) showed~180-fold improvement in binding afﬁnity (KD
D 0.27 nM) and 518-fold improvement in GM-CSF potency
over parental 9A2 (Table S1, Fig. 3A).
With the aim of achieving further potency improvements,
variants 9A2-VR24 and 9A2-VR39 (Fig. 3A) were chosen for
additional afﬁnity optimization. We undertook a combinato-
rial approach where the sequence for either 9A2-VR24 or
9A2-VR39 was ﬁxed and libraries were generated targeting
all residues for CDR H2 with the 9A2-VR24 amino acid
sequence (VR24-H2.1–2.3), and all residues in CDR H1 and
residues 57-65 in CDR H2 with the 9A2-VR39 amino acid
sequence (VR39-H1.1, H1.2, H2.1, H2.3). An additional “off-
rate” selection step was included as all previous potency
improvements correlated with improvements in antibody
off-rates. Unique variants from all selection strategies were
converted to IgG4pK molecules for further analysis in TF-1
proliferation assays. Fig. 3B shows that variants with
improved potency against GM-CSF were generated from
each of the libraries. Improvements in dissociation rate were
observed in those antibodies showing increased afﬁnities
(Table S2 and Fig. 2C). Interestingly, an antibody variant
comprising the combination of the VR24 CDR1 sequence
and the VR39 CDR2 sequence was not identiﬁed as a high
potency inhibitor from this second round of afﬁnity matura-
tion. We generated an antibody containing these sequences,
but there was no potency improvement compared to parental
9A2 (data not shown), supporting the combinatorial
approach that was undertaken.
Variant 9A2-VR24.29 (Fig. 3B) was selected for detailed
study and is hereafter referred to as CSL311. We compared
the ability of CSL311 to inhibit the proliferation of TF-1 cells
in response to IL-3, GM-CSF and IL-5 with parental anti-
bodies 9A2 and 9A2-VR24. CSL311 was signiﬁcantly more
potent than both parental antibodies at inhibiting the prolif-
eration of TF-1 cells in response to all 3 bc-signaling cyto-
kines (Fig. 3C-E) with an IC50 of 0.29 nM against GM-CSF
(Table S2). This equates to a 8.6-fold improvement com-
pared to 9A2-VR24 (2.5 nM) and a 1572-fold improvement
over the parental antibody, 9A2. Improvements in potency
of CSL311 compared to parental 9A2 were also observed for
IL-3 (41-fold, IC50 D 0.144 nM) and IL-5 (310-fold, IC50 D
4.67 nM) (Table S1, Table S2). CSL311 bound to soluble bc
(KD D 100 pM) with a 4.6-fold greater afﬁnity than 9A2-
VR24 due to a further 2.6-fold improvement in dissociation
rate (kd), (Table S2 and Fig. 2C). Human neutrophils and
eosinophils are potently activated by the bc family of cyto-
kines with neutrophils expressing only GM-CSF receptors
and eosinophils expressing receptors for GM-CSF, IL-3 and
IL-5.32,33 The human cell line TF-1 expresses receptors for
GM-CSF, IL-3 and IL-5. In cell surface receptor binding
Figure 2. Afﬁnity maturation of 9A2 results in Fabs with improvements in dissocia-
tion rate (kd) and afﬁnity (KD). Binding of (A) 9A2 Fab, (B) 9A2-VR24 Fab and (C)
9A2-V24.29/CSL311 Fab to immobilized bc was determined by surface plasmon
resonance. Sensorgram (colored) and ﬁtted curves (black) for each concentration
are shown. The kinetic constants can be found in Tables S1 and S2.
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assays we found that 125I-labeled CSL311 bound bc-express-
ing cells with comparable binding afﬁnity, in the range of KD
D 250–730 pM with an average KDD 426 §79 pM
(Table S3). A recombinant Fab fragment of CSL311 bound
with similar or slightly higher afﬁnity than the intact
CSL311, KD D 380–670 pM, suggesting that the IgG form of
CSL311 binds monovalently to cells expressing bc (Table S3).
CSL311 inhibits IL-3, GM-CSF and IL-5 function by binding
to residues in site 2 of bc
We assessed the ability of CSL311 to compete for the binding of
IL-3, GM-CSF, and IL-5 to cells expressing receptors for these
cytokines. Pre-incubation of human eosinophils with CSL311
but not an irrelevant isotype control mAb abolished the bind-
ing of 125I-labeled IL-3 and reduced 125I-labeled IL-5 binding
by 85% (Fig. 4A and Fig. 4C). Pre-incubation of human neutro-
phils with CSL311, but not an irrelevant isotype control mAb,
completely abolished 125I-labeled GM-CSF binding (Fig. 4B).
We next investigated the ability of IL-3, GM-CSF and IL-5
to compete with radio-labeled CSL311 for binding to TF1 cells.
We found that pre-incubation of TF1 cells with IL-3 and GM-
CSF reduced the binding of 125I-labeled CSL311 by 90% at the
highest concentration tested (Fig. 4D). IL-5 pre-incubation also
reduced CSL311 binding but only by 40% (Fig. 4D). The reason
for this is most likely a consequence of the relatively high afﬁn-
ity of the IL-5/Il-5Ra complex, which allows signiﬁcant IL-5
binding even when the contribution of bc is excluded.
34,35
Structural analysis of the CSL311 binding epitope on the bc
receptor
We determined the crystal structure of the Fab fragment of
CSL311 bound to the extracellular domain of bc
27 to gain fur-
ther insights into the mechanism of action of CSL311. As
expected, CSL311 binds to Site 2 on the bc receptor, in particu-
lar to a non-contiguous interface composed of the A-B and E-F
loops of D1 from one bc monomer and the B-C and F-G loops
of D4 from the other bc monomer.
12,27,34,36-39 Superimposition
of the GM-CSF receptor ternary structure (PDB 4NKQ)27 on
the bc/CSL311 complex reveals that CSL311 exerts its inhibi-
tory function on the bc receptor by direct blockade of the cyto-
kine binding site (Fig. 5A). A surface area of 933 A
 2 is buried in
the bc/CSL311 complex and the surface complementarity of the
bc/CSL311 interface (ScD0.59)40 is consistent with the tight
binding afﬁnity of the complex with a KD of 100 pM as mea-
sured by SPR (Table S2). The structure reveals that majority of
the CSL311 contacts with bc are mediated through heavy chain
CDR loops (CDR H1 to H3) (Fig. 5B), consistent with changes
in these CDRs providing the greatest improvements in afﬁnity.
Both hydrophobic and polar contacts contribute to the bind-
ing of CSL311 to bc. CDR H1 main-chain carbonyls of P30 and
W31 make polar contacts with the guanidine side chain of
R364 and main-chain carbonyl of Q101 on the bc receptor
respectively. The side-chain of Y32 from CDR H1 can hydro-
gen bond with the main-chain carbonyl of R364 and can poten-
tially form p-p interactions with Y365 from bc. S53 from CDR
H2 makes polar contacts with S102 from D1 of the bc receptor.
Figure 3. Afﬁnity maturation of 9A2 results in mAbs with improved potency against IL-3, GM-CSF and IL-5. (A) For the ﬁrst round of afﬁnity maturation 6 different CDR
libraries were subjected to 5 rounds of selection in solution with immobilized bc-Fc protein, where the concentration was sequentially reduced with each round. Afﬁnity-
matured phage were isolated and unique variants were re-formatted into full length IgG4 antibodies. Variants 9A2-VR24 (!) and 9A2-VR39 (^) were selected for the
second round of afﬁnity maturation. (B) Afﬁnity-matured phage were isolated and unique variants re-formatted into full length IgG4 antibodies. All afﬁnity-matured var-
iants from each library were tested for potency against GM-CSF in TF-1 proliferation assays and individual IC50 values plotted. 9A2-VR-24.29/CSL311 (~). TF-1 cells were
starved of growth factor for 18 h and then treated with test antibodies 9A2 (), 9A2-VR24 (&) and 9A2-VR24.29/CSL311 (D)) for 30 min prior to the addition of cytokines.
(C) IL-3. (D) GM-CSF. (E) IL-5. Cells were incubated at 37C for 72 h and pulsed with 3[H]-thymidine for the ﬁnal 6 h then harvested onto glass ﬁlters and read on a
b-counter. Histograms show mean and standard error of technical replicates. Experiments were repeated at least 3 times. Representative experiments are shown.
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The side-chain of R52 forms a salt bridge with D107 and it is
also within hydrogen bond distance from the main-chain
amine of V104 on the bc receptor. The side-chain of Y100 from
the CDR H3 of CSL311 hydrogen bonds with bc residues E366
and H367 and forms p-p interactions with Y365 on the bc
receptor. The side-chain of D101 from the CDR H3 makes
polar contacts with the side-chains of Y39, Y421 and the main-
chain amine of V105 on the bc receptor. By comparison the
CSL311 light chain appears to play a more limited role in the
interaction with bc. The side-chain of W32 on CDR L1 makes a
polar contact with the main-chain carbonyl of G420 and van
der Waals contact with the side-chain of Y421. No residues
from CDR L2 make contact with bc. F94 on CDR L3 is within
van der Waals contact of the side-chain T106 from D1 of the
bc receptor. In addition to these contacts, the aromatic side-
chains of Y32 from CDR H1 and Y100 from CDR H3, are bur-
ied in a cleft in the Site 2 interface of bc and form p-p interac-
tions with the side-chains of Y365 and H367 from the bc
receptor, further stabilizing the bc/CSL311 complex (Fig. S1).
Site-directed mutagenesis studies were conducted to deter-
mine the importance of the various interactions between
CSL311 and bc observed in the crystal structure. A total of 32
alanine point mutations of residues in and proximal to the
cytokine-binding site on bc were generated. Using SPR, we
measured the afﬁnities of a puriﬁed Fab fragment of 9A2 to
these mutants relative to bc (Table S4). The binding of a puri-
ﬁed recombinant Fab fragment of CSL311 to key mutants was
evaluated and shown to be similar (Table S4). The most promi-
nent effects were noted for F103A, Q339A and I424A mutants,
which resulted in negligible binding and the I338A mutation,
which resulted in no binding of 9A2/CSL311. Structurally,
F103 and I338 are involved in stabilizing the side chain of Y39,
which makes an important hydrogen bond with the side-chain
of D101 on CDR H3 (Fig. S2). Therefore mutating these resi-
dues may have an effect on the orientation of Y39, which in
turn affects binding of CSL311. Q339 and I424 do not make
any interactions with CSL311, in contrast they are buried deep
in the D1-D4 interface of the bc dimer, therefore the loss of
binding of CSL311 observed for these mutants may be due to a
structural effect on the bc dimer.
The Y39A mutation from D1 of bc resulted in weak binding
of 9A2/CSL311 further emphasizing the importance of Y39 for
high afﬁnity binding to 9A2/CSL311. Mutation of residues
Y365, H367 and I368 from D4 of bc also resulted in weak bind-
ing of 9A2/CSL311. Of these, Y365 and H367 are involved in
making important hydrogen bonds with D101 and Y100 on
CDR H3 respectively. These residues also form a part of the
p-p interaction network comprising Y32 and Y100 from CDRs
H1 and H3, which further emphasizes their role in CSL311
engagement (Fig. S1). Although I368 does not interact with
CSL311 directly, it is part of the hydrophobic groove at the Site
2 interface and may be structurally important for maintaining
proper orientation of the surrounding aromatic side chains of
Y39, Y421, Y365 and H367.
CSL311 inhibits survival of primary human eosinophils
stimulated with IL-3, GM-CSF and IL-5
Eosinophils are the predominant immune effector cells in
atopic asthma, and, through their activation and degranulation,
they are proposed to contribute substantially to airway inﬂam-
mation. The importance of eosinophils in the pathogenesis of
Figure 4. CSL311 competes with IL-3, GM-CSF, and IL-5 for binding to primary human myeloid cells. Puriﬁed human eosinophils (A,C) or neutrophils (B) were pre-incu-
bated with CSL311 () or a human IgG4 control antibody (). Cells were then equilibrated with (A) 340 pM radio-iodinated IL-3, (B) 40 pM radio-iodinated GM-CSF (C)
200 pM radio-iodinated IL-5. Each point is the mean of duplicate determinations of cell-bound radioiodinated cytokine and error bars represent the standard deviation.
Data from representative experiments is shown, nD2. (D) TF-1 cells were pre-incubated with IL-3 (~), GM-CSF (&) or IL-5 () then cells were equilibrated with 85 pM
radio-iodinated CSL311. Each point is the mean of duplicate determinations of cell-bound radio-iodinated CSL311 and error bars represent the standard deviation. Data
from a representative experiment is shown, n D 3.
MABS 441
asthma has been conﬁrmed with the reduction of symptoms
seen in patients treated with antibodies to IL-5 or the IL-5
receptor.15,16,41,42 Human eosinophils also respond to GM-CSF
and IL-3 in addition to IL-5.1 In particular, administration of
recombinant IL-3 or GM-CSF in humans causes a rise in levels
of circulating eosinophils.43 Therefore, in diseases where eosin-
ophilia is a pathogenic feature, all 3 cytokines in combination
may contribute to enhanced eosinophil numbers by mediating
their recruitment from the bone marrow and their increased
survival at the site of pathology. The response of eosinophils to
stimulation with IL-3, GM-CSF and IL-5 is shown in Fig. S3 A-
C. We assessed the ability of CSL311 to block eosinophil
survival in response to a cocktail of all 3 cytokines (at EC80 for
each cytokine). We also assessed individual antagonists
directed against the IL-3Ra,44 GMRa,45 or IL-5Ra,46 alone or
in combination in the same assay. The potency of each individ-
ual receptor antagonist in response to stimulation with their
corresponding cytokine was determined and complete inhibi-
tion was observed at~10 nM for each antagonist (Fig. S3 D-E).
However, in response to a cocktail of all 3 cytokines (at EC80
for each cytokine) inhibition by individual a chain-speciﬁc
antagonists at concentrations above the ICmax in the same assay
was partial. Although the GMRa antagonist was the most
potent inhibitor in this assay the combination of all 3 anti-
Figure 5. The Site 2 Interaction interface between CSL311 and the bc receptor. (A) Superimposition of the bc/CSL311 Fab complex on the GM-CSF receptor ternary struc-
ture, showing the overlap of the interaction interface between CSL311 Fab (heavy chain shown in orange and light chain in yellow) and GM-CSF (gray). The bc dimer
from the GM-CSF ternary structure is colored in green and purple. (B) A surface representation of the key residues on the bc dimer that interact with CSL311 is shown.
Individual residues are colored to indicate the effect of speciﬁc alanine substitution mutations on CSL311 binding afﬁnity: mutations that lead to no binding or negligible
binding are colored in red, mutations that reduce binding to the 10¡5 to 10¡7 M range are shown in yellow and mutations that improve binding are shown in blue. The
detailed interactions involving CDRs H1-H3 and CDR L1 and L3 are shown in the adjoining zoom-in panels. Polar interactions are shown as black broken lines and key van
der Waals interactions are shown in yellow. All ﬁgures were made using PyMOL.
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a chain mAbs provided even greater inhibition of the pro-sur-
vival activity of the cytokine cocktail. In contrast, treatment of
eosinophils with CSL311 at concentrations as low as 200 nM
completely blocked their survival in the presence of the cocktail
of IL-5, GM-CSF and IL-3 (Fig. 6).
CSL311 reduces survival of primary cells isolated and
cultured ex vivo from human airway disease tissue
We next sought to determine whether CSL311 had the same
efﬁcacy on immune cells from asthmatics as it did on cells
derived from healthy donors. We ﬁrst employed the inhaled
allergen bronchoprovocation/challenge model47 to study the
effect of CSL311 on human allergic asthma sputum cells cul-
tured ex vivo. The subject characteristics on screening are
shown in Table S5. In agreement with previous studies, differ-
ential cell counting of the mixed cell population indicated that
the predominant cell types were neutrophils and macrophages,
with a smaller proportion of eosinophils, lymphocytes, and
bronchial epithelial cells (data not shown) and an increase in
sputum eosinophil count is observed 24 h post-allergen chal-
lenge.47 The sputum cells (combined from baseline and 24 h
post-allergen challenge) were cultured ex vivo without exoge-
nous IL-3, IL-5 and GM-CSF, in the presence of CSL311 or iso-
type control mAb, and the effect on their survival investigated
by ﬂow cytometry. CSL311 caused a signiﬁcant decrease in sur-
vival of sputum eosinophils in 5 of 8 subjects (P value D
0.0391) as detected by annexin V staining (Fig. 7A). By con-
trast, survival of neutrophil, lymphocyte or macrophage popu-
lations was unaffected by CSL311. Interestingly, when isolated
sputum cells from the same donors were also incubated with
recombinant human IL-3, IL-5 and GM-CSF (1 ng/ml of each),
CSL311 signiﬁcantly decreased the survival of sputum neutro-
phils (6 out of 8 subjects, P value D 0.0391) and basophils (5
out of 8 subjects, P value D 0.3828) as well as eosinophils (6 of
8 subjects, P value D 0.0078) (Fig. 7B).
Eosinophil and basophil progenitors are found in increased
numbers in peripheral blood and bone marrow in response to
allergen challenge in atopic subjects, a process that can be regu-
lated by IL-3, GM-CSF and IL-5.48 We examined if CSL311
affected the number of CFUs arising from CD34C progenitors
for these populations in bone marrow and blood samples
obtained from asymptomatic allergic asthmatics pre- and 24 h
post- allergen challenge. In the presence of either IL-3, GM-
CSF, IL-5 individually or a combination of all 3 cytokines,
reduced numbers of GM-CFU and Eo/B CFU were counted
when cultured in the presence of CSL311 compared to isotype
control mAb (Fig. 7C-F).
Discussion
IL-3, GM-CSF and IL-5 are a group of pro-inﬂammatory cyto-
kines that signal via a receptor complex composed of a cyto-
kine-speciﬁc a chain and the bc homodimer. They are
implicated in the pathogenesis of chronic inﬂammatory dis-
eases of the airways such as asthma through their ability to
recruit and activate myeloid cells. Here, we describe the genera-
tion and characterization of an antibody that is capable of bind-
ing the bc homodimer and potently inhibiting the functions of
IL-3, GM-CSF and IL-5. Through screening a human Fab
phage library against the entire recombinant extracellular
domain of the bc homodimer combined with a strategy of 2
rounds of afﬁnity maturation targeting all CDRs, apart from
the light chain CDR2, we identiﬁed a number of high afﬁnity,
biologically potent mAbs. CSL311 was selected as a lead candi-
date and demonstrated to effectively neutralize the biological
activities of IL-3, GM-CSF and IL-5 on primary human eosino-
phils at clinically appropriate concentrations.
Evidence from the crystal structure of the bc/CSL311 com-
plex, competitive binding experiments and mutagenesis studies
of key ligand binding residues in the bc receptor conﬁrmed that
CSL311 interfered with the assembly of an active signaling
complex by directly competing with cytokine for binding to bc.
The binding afﬁnity of each cytokine to its cognate receptor a
chain is different for each cytokine, with IL-3 binding with the
lowest afﬁnity (KD D 20-100 nM), GM-CSF with intermediate
afﬁnity (KD D 2–12 nM) and IL-5 with the highest afﬁnity (KD
D 0.8-1 nM).39 Co-expression of bc increases the binding afﬁn-
ity of each cytokine/a chain complex to different extents. Thus,
IL-5 binding afﬁnity is increased 2-5 fold, GM-CSF is increased
20–100 fold and IL-3 is increased 500–1000 fold,39,49-53 result-
ing in a high afﬁnity complexes of KD D 110 pM, 130 pM and
290 pM, respectively.39 These differences are reﬂected in the
ability of CSL311 to compete with cytokine, where increasing
concentrations of CSL311 were required to compete IL-5 com-
pared to IL-3 and GM-CSF. The differences in the ability of
CSL311 to compete with each of the cytokines translated to bio-
logical assays where, although CSL311 demonstrated complete
inhibition of all 3 cytokines, it did so with different potencies.
The lack of any appreciable neutralizing activity of CSL311
against the bc receptor from other species (unpublished observa-
tions) led us to undertake a novel translational medicine
approach utilizing relevant human inﬂammatory airway disease
tissue to assess the potential of this antibody to be effective in dis-
ease situations such as allergic asthma. The widely used inhaled
allergen bronchoprovocation/challenge exacerbation model of
allergic asthma induces many clinical and pathophysiological
Figure 6. CSL311 inhibits the survival of primary human eosinophils cells following
stimulation with bc-signaling cytokines. Eosinophils were pre-treated with CSL311
(~), anti-IL-5Ra (&, 66.7 nM), anti-IL-3Ra (4, 66.7 nM), anti-GMRa (◊, 66.7 nM), or
anti-IL-5Ra/anti-IL-3Ra/anti-GMRa, (, 66.7 nM each mAb) before treatment with
IL-3/GM-CSF/IL-5, for 72h and cell survival determined. No antibody added (&). Data
from representative experiments are shown, n D 5. All values expressed as mean
CSEM. Experiments were repeated at least 4 times with representatives shown.
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features of asthma observed in allergic subjects, including bron-
choconstriction, increased numbers of eosinophils in the sputum
and peripheral blood, and increased numbers of CD34C progen-
itors in bone marrow and peripheral blood. Although relatively
few studies have employed sputum cell culture, it is likely that
cells from the airways will provide highly relevant data due to
their proximity to the site of asthmatic inﬂammation. We used
the techniques of allergen challenge and induced sputum to iso-
late and culture ex vivo induced sputum cells from asymptom-
atic mild allergic asthmatic subjects before and after allergen
challenge. CSL311 was able to signiﬁcantly decrease the survival
of unstimulated eosinophils cultured ex vivo from mild atopic
asthmatic sputum before and after inhaled allergen challenge,
suggesting that the cells were producing factors in vitro that
enhanced their survival that could be blocked by CSL311. This is
consistent with previous observations of delayed eosinophil apo-
ptosis in asthma attributed to the presence of GM-CSF.54
Although eosinophils are key contributors to the pathogenesis of
asthma, other effector cells, including those from the myeloid
lineage contribute to the inﬂammation and the dysregulated
environmental milieu associated with asthma and similar
chronic inﬂammatory conditions. Furthermore, considerable
heterogeneity in inﬂammatory cell measures has been reported
within severe asthma phenotype clusters.55 Interestingly, when a
combination of IL-3, GM-CSF and IL-5 was added to the culture
medium together with CSL311, decreased neutrophil and baso-
phil survival was also observed. This observation shows that one
or more of these cytokines are able to enhance neutrophil and
basophil survival above that provided by endogenous factors
present in the sputum. These data also point to the speciﬁcity of
action of CSL311 as other survival factors in the unstimulated
sputum cell culture, most likely Granulocyte-Colony Stimulating
Factor (G-CSF) in the case of neutrophil survival, are not
affected by CSL311.
In addition to mature eosinophils, circulating common pro-
genitors of eosinophils and basophils are detected in greater
numbers in the peripheral blood of asymptomatic atopic
patients in response to allergen challenge. This involves pro-
duction of Eo/B progenitors in the bone marrow, the release of
both progenitors and progeny from the bone marrow compart-
ment and then recruitment to the respiratory mucosa and other
tissues after which locally produced haematopoietic growth fac-
tors provide further hematopoiesis.56 We examined the ex vivo
effect of CSL311 on early GM and Eo/B progenitors by
Figure 7. CSL311 inhibits survival of cells isolated from human inﬂammatory airway disease tissue. Sputum cells from samples induced at baseline and 24 h after inhaled
allergen challenge from allergic asthmatic subjects were incubated with (A) CSL311 (100 mg/ml) or an isotype control mAb (100 mg/ml) at 37C for 24 h or (B) incubated
with CSL311 (100 mg/ml) or an isotype control mAb (100 mg/ml) at 37C for 24 h in the presence of 1 ng/ml each IL-3, GM-CSF and IL-5. Cells were analyzed for viability
by ﬂow cytometry. Data are expressed as percent cell viability and compared to the isotype control for each donor. Samples where the pre-incubation viability was<10%
were excluded from the analysis. Non-adherent mononuclear cells (NAMC) from (C-D) bone marrow and (E-F) blood samples collected at baseline and 24 h after inhaled
allergen challenge from allergic asthmatic subjects were incubated with CSL311 (100 mg/ml, ﬁlled bars) or an isotype control mAb (100 mg/ml, open bars) at 37C for
24 h in the presence of diluent (neg) or 1 ng/ml each IL-3, GM-CSF and IL-5, or cytokines combined (All) and (C,E) GM CFU and (D,F) Eo/Baso CFU were enumerated. Data
expressed as median § range and 95% conﬁdence intervals. A Wilcoxon matched pairs signed rank 2 tailed t-test was used to determine statistical signiﬁcance: ns, not
signiﬁcant p > 0.05;  p < 0.05;  p < 0.01;  p < 0.005.
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measuring the number of peripheral blood or bone-marrow-
derived GM- or Eo/B CFUs grown in methylcellulose culture.
CSL311 reduced the numbers of GM- and Eo/B-CFU, as
deﬁned by the number of CFU arising from CD34C progenitors
from blood and bone marrow pre- and post- allergen challenge.
By comparison, clinical studies indicated that while mepolizu-
mab caused partial maturational arrest of the eosinophil lineage
it did not fully deplete bone marrow or bronchial eosinophils.
There was no change in the total number of blood or bone mar-
row CD34C cells after mepolizumab therapy nor were there
effects on CD34C/IL-5RaC cells.57 A plausible explanation for
persistence of progenitors and their progeny is the actions of
IL-3 and GM-CSF, which are unaffected by mepolizumab.
Some reports have suggested that sputum eosinophils may dif-
fer from their circulating counterparts due to a decrease in IL-
5Ra expression accompanied by a lack of responsiveness to IL-
5 following allergen challenge and a concomitant increase in
GMRa expression with retained responsiveness to GM-CSF.58
Other studies have also suggested that airway eosinophils are
unresponsive to IL-5 due to down-regulation of IL-5Ra by all 3
bc cytokines whereas they retain their responsiveness to IL-3.
59
In human clinical studies mepolizumab reduced blood and
BALF eosinophils by 100% and 80% respectively but there was
only a 55% reduction in airway mucosal eosinophils.60 In our
in vitro studies, CSL311 blocked eosinophil survival stimulated
with a cocktail of IL-3, GM-CSF and IL-5 to a greater extent
than any of the individual a-chain antagonists alone, and to a
similar extent as the combination of neutralizing mAbs to the
individual a-chains of the IL-3, GM-CSF and IL-5 receptors.
Although CSL311 has a lower IC50 against IL-5 in the TF-1
assay (4.67 nM) compared to the reported IC50 of mepolizumab
(IC50 D 75 pM),61 it is still a complete antagonist of IL-5.
CSL311 therefore may provide a more complete reduction of
sputum eosinophilia through its broader spectrum of activity
compared to anti-IL-5 antagonists through its ability to also
potently inhibit IL-3 and GM-CSF.
The success of corticosteroids as anti-inﬂammatory agents
for a number of diseases including asthma is due to their signiﬁ-
cant pleiotropic effects on a range of key inﬂammatory pathways
and cell types. One known mechanism of action of corticoste-
roids is the inhibition of pro-survival signals from cytokines
such as IL-5, GM-CSF and IL-3 in eosinophils.62 Although single
agents targeting each of these cytokines or their receptor a
chains are currently in clinical development44,45,63,64 and could
conceivably be combined to treat patients with severe asthma,
such an approach would be expected to encounter substantial
practical, regulatory and economic impediments. Our data pro-
vides exciting evidence that a single antibody targeting the bc
homodimer may prove to be a potent and more directed anti-
inﬂammatory therapy in diseases such as asthma when com-
pared to current treatments including corticosteroids. In sup-
port of this view, recent clinical studies have shown that
preventing the expression of human bc using antisense oligonu-
cleotides (TPI ASM8) inhibits the function of eosinophils as well
as basophils and mast cells and is of beneﬁt in attenuating aller-
gen-induced responses in subjects with mild allergic asthma.65
An antibody-based approach directed at bc would be expected
to offer a number of potential advantages over an oligonucleo-
tide-based therapy, including route of delivery, improved
pharmacokinetics and the ability to target bc cytokine responsive
cells within a broader range of tissue types.
Mice lacking the GM-CSF gene or bc/bIL-3 homodimers
develop a pulmonary syndrome of abnormal surfactant
accumulation resembling human Pulmonary Alveolar Pro-
teinosis (PAP).66 However, the absence of signiﬁcant adverse
events in trials using TPI ASM865 and also with antagonists
targeting human GM-CSF (KB003, ClinicalTrials.gov Identi-
ﬁer: NCT01603277),18 human GMRa (mavrilimumab),18
human IL-5Ra (benralizumab) and human IL-5 (mepolizu-
mab, reslizumab)19 is encouraging and suggests that target-
ing bc is unlikely to have signiﬁcant side-effects.
Our study provides the ﬁrst demonstration that targeting bc
with a potent therapeutic mAb (CSL311) can directly inhibit
the survival of multiple primary human cells, including eosino-
phils, neutrophils and basophils in the presence of more than
one cytokine as occurs in an in vivo inﬂammatory setting such
as asthma. Its range of action may also provide advantages
compared with other speciﬁc inhibitors of the IL-3/GM-CSF/
IL-5 pathway. We anticipate that CSL311 will have broad thera-
peutic utility in the treatment of heterogeneous and relatively
poorly understood diseases including, but not limited to, severe
asthma, severe nasal polyposis, COPD, eosinophilic disorders
such as Churg-Strauss syndrome, Hyper-eosinophilic syn-
drome and Eosinophilic Esophagitis and other inﬂammatory




FreeStyleTM 293-F (FS293F) cells and the mammalian expres-
sion vector pcDNA3.1 were obtained from InvitrogenTM,
Thermo Fisher Scientiﬁc (R790-07, V790-20). Cells were cul-
tured in GIBCOFreeStyleTM 293 Expression Medium
(InvitrogenTM, Thermo Fisher Scientiﬁc.12338-018). All tissue
culture media were supplemented with Antibiotic-Antimycotic
(GIBCO, Thermo Fisher Scientiﬁc 15240-096) and cells were
maintained at 37C in incubators with an atmosphere of 8%
CO2.
Cytokines and antibodies
Recombinant human GM-CSF encoding the P6YY substitution
to facilitate radio-iodination was prepared from E.coli as previ-
ously described.67 Recombinant human IL-3 comprising resi-
dues 13–121 and the W13Y substitution to facilitate radio-
iodination was also expressed and puriﬁed from E.coli.68 Car-
rier-free recombinant human IL-5 was purchased from R&D
Systems (205-IL-005/CF). Cytokines (IL-3, GM-CSF) for cellu-
lar assays were purchased from R&D Systems (203-IL-010,
215-GM-010). Anti-IL3Ra antibody44 and anti-GMRa anti-
body69 were prepared as previously described.
Generation of hybridomas
Fifty mg of Hexa-His tagged bc extracellular domain protein
was injected intraperitoneally into BALB/c mice deﬁcient in
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both bc and bIL-3.
13 The mice received a further 2 £ 4 weekly
injections of the same dose at the same site. Spleen cells were
fused with Sp2/0 myeloma cells and hybridomas generated
according to standard methods. Individual hybridomas (3H3),
which was directed against a C-terminal Hexa-His tag, and
anti-human bc mAbs 7H12 and 3F1) were re-cloned by limit-
ing-dilution. Hybridomas were cultured in Hybridoma SFM
(GIBCO, Thermo Fisher Scientiﬁc.12045–076) supplemented
with 0.5–1.0 % low IgG FBS (GIBCO, Thermo Fisher Scien-
tiﬁc16250–078) in roller bottles at 37C.
Generation of cDNA expression plasmids
Human bc cDNA (GenBank Accession no. P32927) and amino
acid mutants of the bc receptor were codon-optimized for
human expression and synthesized by Geneart (InvitrogenTM,
Thermo Fisher Scientiﬁc) each with a Kozak consensus
sequence70 (GCCACC) immediately upstream of the initiating
methionine (C1). Full-length transmembrane bc mutants and
soluble bc variants (truncated after Ser438 with C-terminal 6x
Histidine-tags fused in-frame) were generated using standard
PCR-based mutagenesis techniques. Once each cDNA was
completed, it was digested with NheI and XhoI and ligated into
pcDNA3.1 (InvitrogenTM, Thermo Fisher Scientiﬁc R790-07,
V790-20).
Human IL-3R cDNA (GenBank Accession no. NP_002174),
Human GMRa cDNA (GenBank Accession no. NP_006131)
and Human IL-5Ra isoform 1 cDNA (GenBank Accession no
NP_000555) were obtained either from Dr H. Ramshaw (Center
for Cancer Biology, Adelaide, Australia) or Geneart
(InvitrogenTM, Thermo Fisher Scientiﬁc) and cloned as described
above. Anti-IL-5Ra chain antibody cDNA46,71 was synthesized
by (Geneart, InvitrogenTM, Thermo Fisher Scientiﬁc).
Recombinant Fab fragments of 9A2 and afﬁnity matured
variants were generated by cloning the entire light chain and a
truncated heavy chain, where a stop codon was introduced after
amino acid 241, separately into pcDNA3.1 as described above.
Large-scale preparations of plasmid DNA were carried out
using QIAGEN Plasmid Giga Kits (12191) according to the
manufacturer’s instructions. The nt sequences of all plasmid
constructs were veriﬁed by sequencing both strands using
BigDyeTM Terminator Version 3.1 Ready Reaction Cycle
Sequencing (InvitrogenTM, Thermo Fisher Scientiﬁc.4337455)
and an Applied Biosystems 3130xl Genetic Analyzer.
Transient transfections for generation of recombinant
proteins
Transient transfections of expression plasmids using FS293F
cells were performed using 293fectinTM transfection reagent
(InvitrogenTM, Thermo Fisher Scientiﬁc. 12347–019) as previ-
ously described.72
Antibody puriﬁcation
All mAbs and recombinant Fab fragments were afﬁnity-puri-
ﬁed using HiTrap MabSelectTM SuReTM or KappaSelectTM
(1 ml, GE Healthcare Life Sciences, 11-0034-93, 17-5458-03)
chromatography resins, respectively, and then desalted with a
HiPrepTM 26/10 Desalting column (GE Healthcare Life Scien-
ces 17–5087–01) on an €AKTAxpress high throughput chroma-
tography system (GE Healthcare Life Sciences). Fab fragments
were generated by digestion of the puriﬁed antibodies using
immobilized Papain Agarose (Sigma P4406) and puriﬁed using
Protein A and size exclusion chromatography. The ﬁltered cell
culture media (500 ml) was applied to the column that had
been equilibrated 1 X MTPBS buffer, at a rate of 1 ml/min and
washed sequentially with 1 X MTPBS pH 7.3 (10 ml) and
10 mM Tris, 150 mM NaCl pH 7.2 (80 ml) in the presence of
0.5 M arginine to facilitate endotoxin removal.73 The bound
antibody was then eluted with 8 ml 0.1 M sodium acetate pH
3.0 (or 0.1 M glycine pH 2.5) and immediately applied to the
desalting column. Protein fractions were pooled and concen-
trated using an Amicon UltraCel 50K centrifugal device
(Merck-Millipore) prior to sterile ﬁltration using 0.22 mm ﬁl-
ters. Antibody purity was assessed by SDS-PAGE and protein
visualized using PlusOneTM CoomassieTM Blue PhastGelTM R-
350 Stain (GE Healthcare Life Sciences 17-0518-01), as per the
manufacturer’s instructions, and antibody concentration was
determined chromatographically by comparison to control
antibody standards.
His-tagged protein puriﬁcation
Soluble bc and bc mutants were puriﬁed by tandem Nickel and
size exclusion chromatography on an AKTATM express (GE
Healthcare Life Sciences) puriﬁcation system. Column chroma-
tography was generated as per manufacturer’s instructions.
Post-elution samples were applied directly to a Superdex 200
pg 26/60 column (GE Healthcare Life Sciences 28-9893-36) at
4 ml/min in PBS and fractions collected. Peak fractions con-
taining bc fractions were pooled after additional size exclusion
analysis and sterile-ﬁltered for subsequent testing.
Antibody generation
A human semi-synthetic Fab phage display library was
screened for phagemids that bound the recombinant extracellu-
lar domain of hbc fused to the Fc region of human IgG1 (hbc-
Fc, Human CRC-b-Fc Chimera, Apollo Cytokine Research
1103H) immobilized on Dynabeads M-280 Streptavidin
(InvitrogenTM, Thermo Fisher Scientiﬁc 11205D) by biotin-
anti-human Fc antibody capture (Jackson ImmunoResearch
Laboratories 109–065–098). The selection was done following
methods described previously.74 Three rounds of selection were
performed by incubating the streptavidin bead-depleted phage
input with decreasing concentrations of immobilized hbc-Fc
(15 mg, 10 mg and 5 mg) in 2% milk/PBST (MTPBS, 0.1%
Tween-20) for 20 min at room temperature and then washed
12 times. Selected phage clones were ampliﬁed in log phase E.
coli TG1 cells and the Fab-phagemid rescued by super-infection
with M13K07 helper phage prior to puriﬁcation using standard
protocols.75 Individual clones were picked after the second and
third round of selection and the Fab cassettes and light chains
were PCR-ampliﬁed and sequenced essentially as described.74
Competitive phage ELISA was used to screen for high afﬁnity
clones. Twenty nine unique antibody clones were reformatted
to express full-length IgG4 antibodies with the serine 241 to
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proline hinge region mutation29 and a kappa light chain by
cloning the entire light chain (variable and constant domains)
and the variable domain of the heavy chain from the selected
phage-derived Fab constructs into the pRhG4 vector.76
Afﬁnity maturation of 9A2
Clone 9A2 was afﬁnity-matured by randomization of CDRs
(excluding CDR2 of the light chain) with primers that included
a 19 amino acid combination (without cysteine). Seven differ-
ent libraries were constructed using methods previously
described using “stop template” versions of pTac-geneIII-9A2
Fab where for each phagemid, a germline stop template was
created by replacing 18 codons (6 amino acid residues) in all
CDRs with TAA stop codons.77 Each stop template was used as
a template for the Kunkel mutagenesis method.78 The muta-
genesis reactions were electroporated into E. coli SS320 then
phage production initiated with addition of M13-KO7
helper phage prior to incubation at 30C for 18 h. Phage were
puriﬁed using standard protocols. Mutagenesis efﬁciencies
ranged from 27% to 100% as assessed by sequencing of 12
clones picked randomly from each library. Each library
contained 4 £ 109 – 1.05 £ 1010 individual clones.
Libraries were subjected to 5 rounds of selection in solution
with decreasing concentration of immobilized biotinylated hbc-
Fc. The target concentration was reduced 10-fold with each
round, from 100 nM in Round 1 to 10 pM in Round 5 for all
libraries, except H3.1. In the case of library H3.1, the target
concentration was reduced 10-fold from 100 nM in Round 1 to
10 nM in Round 2, and kept constant at 10 nM in all subse-
quent panning rounds due to a dramatic reduction in phage
output titres at lower target concentrations. Afﬁnity matured
phage were isolated from the libraries essentially as described
above for antibody generation. Unique phage clones were iden-
tiﬁed by sequencing 20 randomly selected clones from each
library. Unique variants were reformatted into full-length
human IgG4/Kappa antibodies as described above.
Variants 9A2-VR24 and 9A2-VR39 were selected for further
afﬁnity maturation and libraries constructed using the methods
described above with mutagenic oligonucleotides. The ﬁrst set
of 3 libraries for the second round of afﬁnity maturation of
9A2 was based on clone VR24 sequence, by generating stop
templates targeting 6 residues at a time in CDR H2. Similarly,
the second set of 4 libraries was based in the VR39 clone
sequence, with 2 libraries in CDR H1 and further 2 in CDR H2.
The mutagenesis efﬁciencies ranged from 50% to 90% as
assessed by sequencing 12 clones selected randomly from each
library. Each library contained 0.25 £ 109 ¡ 2.5 £ 109 individ-
ual clones. Libraries were subjected to 4 rounds of selection in
solution with decreasing concentration of immobilized hbc-Fc,
using methods essentially as described above. The target con-
centration was reduced 10-fold with each round, from 100 pM
down to 1 pM in Round 4.
Following Round 4 of selection, beads with 1 pM output
phage and the corresponding blank sample were washed as
described above and resuspended in PBS. Half was subse-
quently eluted with 50 mM dithiothreitol (DTT) and the eluted
and neutralized phage were designated as 1 pM output. The
second half was used to select for variants with improved off-
rates, designated Off-rate output, by incubation at room tem-
perature for 1 h in the presence of excess immobilized hbc-Fc
(1 nM) followed by washing, elution and neutralization as
described above. Unique variants from each library were identi-
ﬁed by sequencing and reformatted into fully human IgG4
/kappa antibodies as described above.
ELISA
Phagemid-Fab clones were tested for target binding by ELISA.
Puriﬁed hbc-Fc protein or irrelevant human IgG antibody were
coated at 2 mg/ml in MTPBS; pH 7.3 onto 96-well MaxiSorpTM
ELISA (Sigma M9140) plates overnight at 4C. Plates were
blocked for 2 h at 37C with 200 ml/well of 5% skim milk/
PBST, washed twice with PBST before incubation with phage
supernatant (100 ml/well) for 90 min at room temperature.
Plates were washed x 5 with PBST prior to incubation with
anti-M13-HRP antibody (GE Healthcare Life Sciences
27942101) diluted 1:10,000 in PBST. Plates were washed x6
with PBST and signal developed with 100 ml TMB/E substrate
(Merck Millipore ES001-500ML). The reaction was stopped
with 2 M phosphoric acid (50 ml/well) and measured at
450 nm. To determine approximate binding afﬁnities of phage-
mid clones to hbc-Fc protein, competition ELISAs were per-
formed. The phage supernatant was diluted with 2% skim
milk/PBST to give an absorbance 450 nm value of 1.5 from
extrapolating phage titration ELISA results. Prior to addition of
50 ml/well of appropriately diluted phage supernatant, an equal
volume of competitor bc-Fc protein was added per well at a
starting concentration of 2.5 mM and subsequently diluted 4-
fold in 2% skim milk/PBST.
Binding afﬁnity determination
Binding kinetics were measured using SPR with a BIAcore A-
100 instrument (GE Healthcare Life Sciences). An anti-C-ter-
minal Hexa-His antibody (manufactured in-house) was immo-
bilized on spots 1, 2, 4 and 5 of each ﬂow cell of a CM-5 sensor
chip (GE Healthcare Life Sciences) using amine-coupling
chemistry. The typical immobilization level was between 13000
and 15000 response units (RU).
As bc is a dimer, avidity effects were avoided by performing
kinetics assays with bc extracellular domain captured on the sen-
sor surface, and puriﬁed Fab injected as the analyte. bc was cap-
tured on spots 1 and 5 of each ﬂow cell for 2 min at a
concentration of 0.4 mg/ml. For 9A2 analysis, puriﬁed Fab was
injected over each ﬂow cell for 2 min and dissociation was moni-
tored for a further 5 min. For CSL311 analysis, puriﬁed Fab was
injected over each ﬂow cell for 3 min and dissociation was moni-
tored for a further 10 min. Regeneration of the surface was per-
formed after each cycle with a 40 second injection of 25 mM
glycine, pH 2.0. The analysis was performed with Fabs at several
concentrations between 100 and 0.31 nM, with each concentra-
tion analyzed twice and in random order. The analysis was per-
formed at a ﬂow rate of 30 ml/min in HBS-EP buffer (10 mM
Hepes, 150 mM NaCl, 3 mM EDTA, 0.005% Tween 20, pH 7.4)
at 37C. Responses from spots 2 and 4 of each ﬂow cell, (in which
bc was not captured, but otherwise treated identically), were sub-
tracted from those of spots 1 and 5, respectively, to produce
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reference-subtracted data. Reference subtracted responses from a
blank injection comprising buffer alone were subtracted from the
resultant sensorgrams to produce double referenced data suitable
for kinetic analysis. Double-referenced sensorgrams were ﬁtted
using non-linear regression to a model describing 1:1 kinetics,
including a term for mass transport limitation. The Rmax value
was ﬁtted locally to account for slight deviations in the level of bc
captured, with association rate (ka), dissociation rate (kd) and
equilibrium dissociation constant (KD) ﬁtted globally.
Epitope mapping
Mapping of the CSL311 epitope on bc was performed by mea-
surement of the afﬁnity of 9A2 and CSL311 Fabs for various ala-
nine point mutants of bc essentially as described above, with the
following exceptions. Each bc mutant was captured for 120 sec-
onds at concentrations between 1 and 5 mg/ml. For kinetic anal-
ysis, puriﬁed recombinant Fabs of 9A2/ CSL311 were injected
for 2 min, and dissociation was monitored for a further 2 min.
For steady-state afﬁnity analysis, Fab was injected for 2 or 3 min
and dissociation monitored for 60 seconds. Fab concentrations
ranged from 16 mM to 3.9 nM in two-fold dilutions. The assays
were conducted at 25C. All sensorgrams were reference sub-
tracted as described above. For determination of steady-state
afﬁnity (KD only), the response at the end of the binding phase
was used to ﬁt the data to a single-site binding model. Kinetic
parameters were determined as described above. The kinetics of
2 control anti-human bc Fabs (7H12 and 3F1) with epitopes dis-
tinct from 9A2 were also determined for each point mutant to
establish whether the mutation had caused structural perturba-
tions to bc. 7H12 and 3F1 bind epitopes within domain 4 and 3
of bc, respectively (data not shown).
Crystallization of the bc/CSL311 Fab complex
The bc/CSL311 Fab complex was puriﬁed from a mixture of
monomeric components27 by size exclusion chromatography.
All crystallization trials of the complex were carried out at
18C using commercially available protein crystallization
screens with the protein at a concentration of 6 mg/ml. Initial
crystallization trials were set up using a Art Robbins liquid han-
dler (Gryphon) in 96-well sitting drop format. Rectangular
plate shaped crystals appeared between 2-3 d in 40% PEG 200
and 100 mM Tris pH 8.5 from the PEGs Suite (Qiagen
130904). Crystals were optimized by the hanging-drop vapor-
diffusion method. Although several crystal forms of the bc/
CSL311 Fab complex were obtained, these crystals typically dif-
fracted to 8A

resolution. Several pre-crystallization and post
crystallization methods were used to optimize crystal diffrac-
tion. Finally treatment of crystals with 0.3% to 1 % of gluteral-
dehyde (Sigma-Aldrich 111-30-8) for 15 minutes to 1 hr





ing several crystals, 3 partial datasets were combined to obtain
complete data set at 3.9 A

resolution (Table S6).
Structure determination of bc/CSL311 Fab complex
Data collection was carried out with a 20% attenuated beam at
the MX2 beam line at the Australian Synchrotron.79 The
crystals belonged to the C2 space group with unit cell dimen-
sions of a D 99.95, b D 71.28, c D 221.23. Data were scaled and
processed using XDS80 and Aimless81 and molecular replace-
ment was carried out using Phaser (CCP4 suite).82 The bc ecto-
domain structure (PDB 2GYS)83 was modiﬁed to a partial bc
dimer consisting of domains D4 and D1 only and was used as a
search model to locate the bc molecule. The CSL311 Fab mole-
cule was located using PDB 3HI5 as the search model (sequence
similarity of~84% for heavy chain of CSL311)84 after deleting the
CDR loops. A single solution comprising a partial bc dimer
(comprising domains D1 and D2 from monomer A and
domains D3 and D4 from monomer B) and one molecule of the
CSL311 Fab comprising heavy (H) and light (L) chains was
obtained with an Rwork/Rfree of 0.38/0.45 after ﬁrst round of rigid
body reﬁnement. Initial electron density was clearest for the Fab
molecule and domains D4 and D1 of bc, while density for bc
domains D2 and D3 was the weakest. The initial bc/CSL311
model was further improved by iterative cycles of model build-
ing in Coot and model reﬁnement using Phenix.85-87
Although the electron density maps for domains D4 and D1
of bc and the variable domains of Fab H and L chains was con-
tinuous, no electron density was observed for parts of D2 and
D3 of bc and parts of the constant domains of the Fab H and L
chains even at the end of reﬁnement, suggesting that they might
be either highly ﬂexible or adopt multiple conformations. The
structure was reﬁned to a ﬁnal Rwork/Rfree of 0.30/0.34. The
structure was validated using Molprobity.88 The coordinates
for the structure have been deposited with the RCSB Protein
Data Bank (PDB 5DWU).
Cell surface receptor binding assays
Recombinant cytokines and antibodies were radio-iodinated
using Pierce Pre-Coated Iodination tubes (Thermo Scien-
tiﬁcTM, Thermo Fisher Scientiﬁc 28601) according to the man-
ufacturer’s instructions. MAb binding to cells expressing bc
was determined by incubating 1-2 £106 cells with radio-iodin-
ated mAb at a range of concentrations at 23C for 1-2 h with
gentle mixing. Cell suspensions were then centrifuged through
fetal calf serum (FCS) and radioactivity associated with the cell
pellets was assessed by counting in a Wizard2 2470 Automatic
Gamma Counter. Non-speciﬁc binding was assessed for each
radio-iodinated mAb in the presence of at least a 500-fold
excess of unlabeled mAb. Dissociation constants and receptor
numbers were calculated using the EBDA and LIGAND pro-
grams89 (KELL Radlig, Biosoft). Competition binding assays
were performed essentially as previously described.25 Brieﬂy 1-
2 £106 cells were incubated with mAb at a range of concentra-
tions at 4C for 45 min with gentle mixing. Radio-iodinated
cytokine was then added and the mixture incubated at 23C for
a further 1-2 h with gentle mixing. Cell suspensions were then
centrifuged through FCS and radioactivity associated with the
cells pellets assessed by counting.
TF-1 proliferation assays
TF-1 cells were maintained in RPMI media with 10% FCS, 1 x
glutamine, 1 x Antibiotic Antimycotic and 2 ng/ml hGM-CSF at
37C and 5% CO2. Cells were starved of growth factor for 18 h,
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plated in 96 well ﬂat bottom plates at 1 £ 104 cells/well then
treated with test antibodies for 30 min prior to the addition of IL-
3, IL-5 or GM-CSF. Cells were incubated at 37C and 5% CO2 for
72 h and pulsed with 3[H]-thymidine for the ﬁnal 6 h before har-
vesting to glass ﬁlters. 3[H]-thymidine incorporation was deter-
mined by liquid-scintillation counting with a Beckman b-counter.
Cell signaling assays
GeneBLAzer TF-1 bla pStat5 assay
TF-1 bla cells (InvitrogenTM, Thermo Fisher Scientiﬁc K1637)
were cultured in RPMI media 1640 (Gibco Thermo Fisher
Scientiﬁc 72400–047) with 10% FCS, 0.1 mM Non-Essential
Amino Acids (NEAA, Gibco Thermo Fisher Scientiﬁc 11140–
050) 1 mM sodium pyruvate, Blasticidin (InvitrogenTM,
Thermo Fisher Scientiﬁc.A11139–02) (5 mg/ml) and hGM-CSF
(2 ng/ml). Prior to assay, cells were washed 3 x with PBS with
0.1% FCS to remove growth factor then resuspended in assay
media (Opti-MEM, Gibco Thermo Fisher Scientiﬁc 11058–
021) with 0.5% FCS, 0.1 mM NEAA, 1 mM sodium pyruvate,
Antimycotic-Antibiotic, and incubated at 37C and 5% CO2
for 18 h. Cells were plated in assay media at 1.2 £ 105 cells per
well in 96-well ﬂat, clear bottom, black-walled plates then
treated with test antibodies for 30 min prior to the addition of
1 ng/ml IL-3 or GM-CSF Cells were incubated at 37C and 5%
CO2 for 5 h then FRET B/G substrate (InvitrogenTM, Thermo
Fisher Scientiﬁc, K1095, K1096, K1030) added for 2.5 h before
reading (EnVision, Perkin Elmer).
Isolation of neutrophils and eosinophils
Eosinophils were isolated from the buffy coats from healthy
donors (Australian Red Cross Blood Service (ARCBS), Mel-
bourne, Victoria and Adelaide, South Australia). Peripheral
blood mononuclear cells were separated from granulocytes and
red blood cells by centrifugation over Ficoll-PaqueTM PLUS
(GE Healthcare Life Sciences 71-7167-00-AG) density gra-
dients. Neutrophils were separated from the red blood cell pel-
let by dextran sedimentation. Neutrophils were washed with
cold PBS and red-blood cells were lysed by hypotonic shock.
The red blood cell pellet containing granulocytes was lysed
with Ammonium Chloride Solution (Stem Cell Technologies
07850) and eosinophils were isolated using a MACS Eosino-
phil Isolation Kit (Miltenyi Biotec 130–092–010).
Eosinophil survival assays
Puriﬁed eosinophils were plated at 1 £ 104/well in ﬂat bottom
96-well plates then test antibodies were added for 30 minutes
prior to the addition of IL-5, IL-3 and GM-CSF. Cells were
incubated at 37C and 5% CO2 for 5 d and cell number deter-
mined with the ViaLightPlus Cell Proliferation and Cytotox-
icity BioAssay Kit (Lonza LT17–221).
Inhaled allergen challenge assays
Subjects with stable, mild atopic asthma who were also non-
smokers, free of other lung diseases and not pregnant with
baseline FEV1 70 % of predicted were chosen for allergen
challenge. The allergen challenge study was approved by the
McMaster Faculty of Health Sciences/Hamilton Health Scien-
ces Research Ethics Board (project 12-583) and signed
informed consent was obtained from subjects. Allergen chal-
lenge was performed as previously described.90 Sputum sam-
ples were mixed in PBS (without DTT) to disperse the cells,
and the mixture ﬁltered to remove mucus before centrifuga-
tion. The cell pellet was resuspended at a concentration of 1
£ 106 cells/ml in RPMI with100 U/ml pen/strep (Gibco,
15140-122) and 10% FCS (Sigma, C8056). A cytospin was
made for differential cell counting, including percentage eosi-
nophils, neutrophils, macrophages, lymphocytes, and bron-
chial epithelial cells. The mixed cell population was cultured
either with no growth factors or in the presence of 1 ng/ml
each recombinant human IL-3 (R&D Systems, 203-IL-010),
GM-CSF (R&D Systems, 215-GM-010) and IL-5 (R&D Sys-
tems, 205-IL-005) and incubated at 37C in a humidiﬁed
incubator with 5% CO2 with CSL311 at a ﬁnal concentration
of 100 mg/ml. Outcomes were compared to incubation with
an irrelevant isotype control mAb at a ﬁnal concentration of
100 mg/ml. After 24 h, the cells were removed from the wells,
washed, and re-suspended in Binding Buffer (BD PharMingen,
556454). The cells were co-stained with speciﬁc cell lineage
markers using the following antibodies and isotype controls:
anti-CD16 FITC (BD PharMingen, 555406), anti-IgG1 FITC
(BD PharMingen, 555786), anti-CD3 PeCy7 (BD PharMingen,
563423), anti-IgG1 PeCy7 (BD PharMingen, 561298), anti-
CD68 APC (Biolegend, 333809), anti-IgG2b APC (Biolegend,
401209), Siglec 8-PE (Biolegend, 347103) and anti-IgG1 PE
(Biolegend, 406607), and the viability of speciﬁc populations
evaluated at baseline and 24 h post allergen-challenge. Cul-
tures where the baseline viability was less than 10% were
excluded from the analysis.
Preparation of bone marrow and peripheral blood cells for
quantiﬁcation of Eo/Baso-CFU and GM-CFU from CD34C
cells populations
Blood samples (80 ml) and bone marrow aspirates (5 ml) were
collected as previously described from mild atopic asthmatic
subjects pre- and 24 h post-allergen challenge.91 Low-density
mononuclear cells (MNCs) were isolated by sedimentation on
AccuprepTM density gradients (Cedarlane, AN551).92 Non-
adherent mononuclear cells (NAMNCs) were resuspended in
Iscove’s 2C (Iscove’s modiﬁed Dulbecco’s medium with 1%
pen/strep (Gibco, 15140-122) and 1% 2-mercaptoethanol
(Sigma, M3148) and placed in Methocult cultures (StemCell
Technologies, Inc., 04236) in the presence of 16% fetal bovine
serum (Sigma, 13G210) and IL-5 (10 ng/ml) (R&D Systems,
205-IL-005), IL-3 (25 ng/mL) (R&D Systems, 203-IL-010),
GM-CSF (10 ng/ml) (R&D Systems, 215-GM-010), or a combi-
nation of all 3 growth factors. The NAMNC cells were cultured
at a concentration of 0.5 £ 106 cells/ml for 2 weeks at 5% CO2,
with high humidity at 37C. The number of Eo/B CFU was
quantiﬁed in duplicate plates using an inverted light micro-
scope at 40x magniﬁcation and the average number of colony-
forming units per plate was calculated. A colony was deﬁned as




For the comparison of matched non-parametric samples we
used the Wilcoxon rank-sum t test. P values of less than .05
were considered statistically signiﬁcant. Unless otherwise speci-
ﬁed all data are presented as means §SEM, and data are from
at least 3 independent experiments (all measurements for each
in vitro experiment performed in at least duplicate). Statistical
analyses were calculated using GraphPad Prism version 6.0.
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